NasdaqGS:ABCLLife Sciences
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets
AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635.
ABCL635 is a non hormonal candidate for treating moderate to severe vasomotor symptoms associated with menopause.
This Phase 2 dosing milestone marks further clinical progress in the company's efforts to develop a potential first in class menopause therapy.
AbCellera Biologics, known for its antibody discovery platform, is pushing deeper into clinical development...